Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	203.86	230.44	4.16
Cash & Short-Term Investments	203.86	230.44	4.16
Cash Growth	-	5442.09%	-
Receivables	-	0.07	0.07
Prepaid Expenses	2.22	0.57	0.76
Total Current Assets	206.08	231.07	4.98
Property, Plant & Equipment	0.62	0.82	0.64
Other Long-Term Assets	2.09	2.03	0.94
Total Assets	208.78	233.98	6.7
Accounts Payable	4.68	3.19	5.14
Accrued Expenses	11.08	11.61	18.76
Current Portion of Leases	0.3	0.29	-
Total Current Liabilities	16.07	15.09	23.9
Long-Term Leases	0.22	0.37	-
Other Long-Term Liabilities	-	0.02	0.09
Total Liabilities	16.28	15.47	23.98
Common Stock	0	0	0
Additional Paid-In Capital	7.8	4.25	2.23
Retained Earnings	-182.58	-153.02	-101.04
Total Common Equity	-174.78	-148.77	-98.8
Shareholders' Equity	192.5	218.51	-17.28
Total Liabilities & Equity	208.78	233.98	6.7
Total Debt	0.52	0.66	-
Net Cash (Debt)	203.34	229.78	4.16
Net Cash Growth	-	5426.29%	-
Net Cash Per Share	292.98	396.10	9.69
Filing Date Shares Outstanding	34.26	34.26	0.43
Total Common Shares Outstanding	34.26	0.64	0.43
Working Capital	190.01	215.99	-18.91
Book Value Per Share	-5.10	-232.15	-230.26
Tangible Book Value	-174.78	-148.77	-98.8
Tangible Book Value Per Share	-5.10	-232.15	-230.26

Source: S&P Capital IQ. Standard template. Financial Sources.